InicioMOR • ETR
add
Morphosys
Cierre anterior
67,65 €
Intervalo diario
67,65 € - 68,00 €
Intervalo anual
14,52 € - 69,75 €
Cap. bursátil
2551,52 M EUR
Volumen medio
66,52 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
ETR
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (EUR) | mar 2024info | Cambio interanual |
|---|---|---|
Ingresos | 27,54 M | 13,11 % |
Gastos operativos | 289,14 M | 264,02 % |
Ingresos netos | -314,96 M | -608,87 % |
Margen de beneficio neto | -1,14 mil | -526,67 % |
Beneficios por acción | -8,27 | -529,19 % |
EBITDA | -263,38 M | -388,32 % |
Tipo impositivo efectivo | 0,51 % | — |
Balance general
Activos totales
Responsabilidades totales
| (EUR) | mar 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 630,77 M | -20,30 % |
Activos totales | 1831,53 M | -17,85 % |
Responsabilidades totales | 2093,20 M | -1,84 % |
Patrimonio total | -261,67 M | — |
Acciones en circulación | 37,62 M | — |
Precio-valor contable | -9,72 | — |
Rentabilidad económica | -34,27 % | — |
Retorno sobre capital | -41,11 % | — |
Flujo de caja
Variación neta del flujo de caja
| (EUR) | mar 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | -314,96 M | -608,87 % |
Efectivo de operaciones | -71,53 M | 14,27 % |
Efectivo de inversión | 28,62 M | 187,62 % |
Efectivo de financiación | -950,28 mil | 97,86 % |
Variación neta del flujo de caja | -27,24 M | 75,37 % |
Flujo de caja libre | 246,91 M | 1.523,66 % |
Información sobre la empresa
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG is listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024. Wikipedia
Director ejecutivo
Fundación
1992
Sitio web
Empleados
464
